CRH Medical (NYSEAMERICAN:CRHM) had its price objective boosted by Canaccord Genuity from $3.00 to $3.50 in a research report report published on Friday, AnalystRatings.com reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently issued reports on CRHM. Royal Bank of Canada dropped their price objective on shares of CRH Medical from $4.75 to $4.00 and set an outperform rating on the stock in a report on Thursday, May 14th. Zacks Investment Research upgraded shares of CRH Medical from a strong sell rating to a hold rating in a research note on Friday, June 19th. Finally, Beacon Securities lowered CRH Medical from a buy rating to a hold rating in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $3.67.

CRHM stock opened at $2.09 on Friday. CRH Medical has a 1 year low of $0.86 and a 1 year high of $4.43.

CRH Medical (NYSEAMERICAN:CRHM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.04). The business had revenue of $25.46 million during the quarter, compared to analyst estimates of $28.70 million.

In other news, Director David Allan Johnson purchased 15,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $1.98 per share, for a total transaction of $29,700.00.

A number of large investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in CRH Medical by 14.3% in the 4th quarter. Bank of America Corp DE now owns 59,466 shares of the company’s stock worth $207,000 after purchasing an additional 7,422 shares in the last quarter. Vestor Capital LLC purchased a new position in shares of CRH Medical in the fourth quarter worth $55,000. Spark Investment Management LLC bought a new position in shares of CRH Medical during the fourth quarter worth $62,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in CRH Medical by 1.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,148,535 shares of the company’s stock valued at $7,456,000 after acquiring an additional 27,800 shares in the last quarter. Finally, 1832 Asset Management L.P. purchased a new stake in CRH Medical in the 1st quarter worth $41,000.

CRH Medical Company Profile

CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.

Featured Story: Most Active Stocks

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.